Business Context and Reporting Period
Company: EXICURE, INC.
Filing Type: Form 8-K (Current Report)
Date: July 15, 2021
Context: The filing announces a virtual R&D Day scheduled for July 15, 2021, to showcase the company's neuroscience pipeline. The primary focus is an update on the lead product candidate, XCUR-FXN, which targets the molecular cause of Friedreich's Ataxia.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
No material financial changes or comparative period data are reported in this document. The filing serves solely to disclose the upcoming R&D Day event under Regulation FD.
Outlook and Management Commentary
- Event Details: A virtual R&D Day was held from 10:00 am to 11:00 am ET on July 15, 2021.
- Pipeline Focus: Management highlighted the neuroscience pipeline, specifically providing updates on XCUR-FXN for Friedreich's Ataxia.
- Access: A live webcast was available on the company website, with an archived version made available post-event.
- Legal Status: The information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability and incorporation by reference.
Key Facts for Investor Verification
- Verify the content of the archived R&D Day presentation for specific clinical data or timeline updates regarding XCUR-FXN.
- Confirm the company's cash runway and funding status in subsequent filings (e.g., 10-Q or 10-K), as this 8-K contains no financial data.
- Monitor the Nasdaq listing status (Symbol: XCUR) for any trading halts or volatility following the R&D Day disclosures.